J&J, Rallybio partner on drug development for rare fetal condition

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 10, 2024 at 06:02: PM
via Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for a rare disorder known as fetal and neonatal alloimmune thrombocytopenia, or FNAIT.

article source
 

<



Similar threads

cafead
Rallybio reins in preclinical R&amp;D, while Monopar pivots to radiopharma to eke out cash
Replies
0
Views
60
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
At J&amp;J, oncology R&amp;D meets commercial strategy in a quest for new standards of care
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Agency warns J&amp;J over 340B rebate plan
Replies
0
Views
25
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: J&amp;J cues up phase 3 for Rybrevant in colorectal cancer
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA pushed to be more open, collaborative to accelerate rare disease R&amp;D
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote